Compare Gilead Sciences, Inc. (GILD) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $150.84 (market cap $182.40B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.36 (market cap $28.50B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× iShares iBoxx $ Inv Grade Corporate Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| GILD | LQD | |
|---|---|---|
Market Cap | $182.40B | $28.50B |
Volume | 4,469,821 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $112.91 |
52-Week Low | $116.74 | $101.83 |
Typical Hold Time | 111 Days | 125 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.
The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
